Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.24
Percentage change 7.38	%

Peers: NTLA CRSP EDIT RGNX BLUE SGMO ALLO FATE PSTX BEAM

| Held by: IWM XBI VTI IWO VXF VB IBB SCHA SMLF VBK

Index	RUT	P/E	-	EPS (ttm)	-1.41	Insider Own	45.04%	Shs Outstand	223.11M	Perf Week	0.00%
Market Cap	779.20M	Forward P/E	-	EPS next Y	-0.87	Insider Trans	-0.58%	Shs Float	122.70M	Perf Month	116.77%
Income	-305.81M	PEG	-	EPS next Q	-0.25	Inst Own	53.36%	Short Float	40.98%	Perf Quarter	-10.97%
Sales	0.00M	P/S	-	EPS this Y	17.68%	Inst Trans	3.83%	Short Ratio	7.55	Perf Half Y	-40.55%
Book/sh	1.31	P/B	2.66	EPS next Y	27.22%	ROA	-51.36%	Short Interest	50.28M	Perf Year	-41.64%
Cash/sh	0.91	P/C	3.84	EPS next 5Y	17.56%	ROE	-92.90%	52W Range	1.52 - 12.00	Perf YTD	114.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-83.13%	ROI	-80.91%	52W High	-70.92%	Beta	1.60
Dividend TTM	-	Quick Ratio	4.47	Sales past 5Y	0.00%	Gross Margin	-	52W Low	129.61%	ATR (14)	0.54
Dividend Ex-Date	-	Current Ratio	4.47	EPS Y/Y TTM	1.99%	Oper. Margin	-	RSI (14)	58.62	Volatility	10.81% 18.43%
Employees	328	Debt/Eq	0.33	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.57	Target Price	10.75
Option/Short	Yes / Yes	LT Debt/Eq	0.29	EPS Q/Q	-5295.92%	Payout	-	Rel Volume	0.80	Prev Close	3.25
Sales Surprise	-	EPS Surprise	2.76%	Sales Q/Q	-	Earnings	Nov 08 BMO	Avg Volume	6.66M	Price	3.49
SMA20	15.33%	SMA50	37.92%	SMA200	-29.96%	Trades		Volume	5,313,554	Change	7.38%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-25	Upgrade	TD Cowen	Hold → Buy
Nov-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-26-24	Initiated	Rodman & Renshaw	Buy	$16
Jan-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Sep-25-23	Initiated	JMP Securities	Mkt Outperform	$9
Sep-05-23	Initiated	Citigroup	Buy	$8
Aug-14-23	Initiated	TD Cowen	Market Perform
May-02-23	Initiated	H.C. Wainwright	Neutral
Mar-01-21	Initiated	Morgan Stanley	Overweight	$40
Mar-01-21	Initiated	JP Morgan	Neutral	$35
Mar-01-21	Initiated	Goldman	Neutral	$40
Mar-01-21	Initiated	BofA Securities	Buy	$45

Show Previous Ratings

Jan-28-25 10:42AM	Sana Biotechnology, Inc. (SANA): A Bull Case Theory (Insider Monkey)
Jan-22-25 07:59AM	Is Sana Biotechnology, Inc. (SANA) the Hottest Smid-Cap Stock So Far In 2025? (Insider Monkey) +19.86%
Jan-08-25 04:05PM	Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +160.61% -14.88%
10:34AM	Sana Biotechnology (SANA), eBay (EBAY) Are Among Todays Big Winners (Insider Monkey)
10:11AM	This Biotech Stock Soared 300% Overnight. Why It Can Go Higher. (Barrons.com)
07:26AM	Loading…
07:26AM	Sana Biotechnology price target lowered to $7 from $8 at BofA (TipRanks)
07:25AM	This Biotech Stock Just Soared 240%. Why It Can Go Higher. (Barrons.com)
06:31AM	Tenvie raises $200M for brain drug R&D; Sana spikes on single patients results (BioPharma Dive)
Jan-07-25 04:05PM	Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression (GlobeNewswire) -5.71%
Dec-02-24 09:00AM	Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus (GlobeNewswire)
Nov-25-24 04:05PM	Sana Biotechnology to Present at December 2024 Investor Conferences (GlobeNewswire)
Nov-20-24 08:00AM	Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies (PR Newswire) +7.20%
06:30AM	Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer (PR Newswire)
Nov-13-24 09:55AM	Here's Why Sana (SANA) Could be Great Choice for a Bottom Fisher (Zacks) -6.34%
08:00AM	Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio (PR Newswire)
08:00AM	Loading…
08:00AM	Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner (PR Newswire)
Nov-11-24 09:35AM	Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround (Zacks)
Nov-08-24 09:10AM	Sana: Q3 Earnings Snapshot (Associated Press Finance)
09:00AM	Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Nov-05-24 04:40AM	Sana to lay off staff, deepen autoimmune focus in latest retrenchment (BioPharma Dive) -9.84%
Nov-04-24 04:30PM	Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025 (GlobeNewswire)
Oct-23-24 08:00AM	Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence (PR Newswire)
Oct-16-24 08:58AM	Why Sana Biotechnology, Inc. (SANA) is the Penny Stock with the Biggest Upside Potential According to Analysts (Insider Monkey)
Oct-13-24 04:48PM	Sana Biotechnology, Inc. (SANA): Jeff Bezos Is Buying This Stock Now (Insider Monkey)
Oct-09-24 07:00AM	Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions (PR Newswire)
Oct-03-24 08:00AM	Invaio Sciences Appoints Andr Andonian as Chairman of the Board of Directors (PR Newswire)
Sep-30-24 04:05PM	Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference (GlobeNewswire)
Sep-26-24 06:00AM	Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry (PR Newswire) +13.56%
Aug-29-24 04:05PM	Sana Biotechnology to Present at September 2024 Investor Conferences (GlobeNewswire)
Aug-28-24 06:30AM	Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer (PR Newswire)
04:05PM	Loading…
Aug-26-24 04:05PM	Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer (GlobeNewswire)
Aug-08-24 05:03PM	Sana: Q2 Earnings Snapshot (Associated Press Finance) +5.36%
04:05PM	Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Aug-06-24 06:30AM	Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner (PR Newswire)
Jul-29-24 07:00AM	GSK and Flagship Pioneering partner to discover novel medicines and vaccines (PR Newswire)
Jul-25-24 08:00AM	Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World (PR Newswire)
Jul-23-24 06:00AM	Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class (PR Newswire)
Jul-17-24 08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire) -7.00%
Jul-10-24 06:00AM	Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations that Transform Human Health and Sustainability (PR Newswire)
06:00AM	Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions (PR Newswire)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire)
May-21-24 09:00AM	Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington's Disease and Other Glial-based Neurodegenerative Conditions (GlobeNewswire)
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia) -7.77%
May-10-24 01:35PM	Sana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-09-24 07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire) -20.97%
May-08-24 10:55PM	SANA Stock Earnings: Sana Biotechnology Meets EPS for Q1 2024 (InvestorPlace) -5.48%
05:22PM	Sana: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
May-06-24 04:05PM	Sana Biotechnology to Present at May and June 2024 Investor Conferences (GlobeNewswire)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-19-24 10:00AM	CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) (GlobeNewswire)
08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire)
Mar-11-24 07:00PM	Director Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA) (GuruFocus.com)
Mar-07-24 09:01AM	Baillie Gifford Bolsters Stake in Sana Biotechnology Inc (GuruFocus.com)
Feb-29-24 04:55PM	Sana: Q4 Earnings Snapshot (Associated Press Finance) -5.90% +12.25%
04:05PM	Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates (GlobeNewswire)
03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Feb-28-24 04:05PM	Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference (GlobeNewswire) +7.34%
Feb-13-24 04:05PM	Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP (GlobeNewswire) +15.15%
Feb-12-24 04:05PM	Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-08-24 01:22AM	Sana Biotechnology Announces Pricing of Upsized Public Offering (GlobeNewswire)
Feb-07-24 04:01PM	Sana Biotechnology Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-27-24 11:02AM	Baillie Gifford Reduces Stake in Sana Biotechnology Inc (GuruFocus.com)
Jan-18-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice (Zacks) -7.68%
10:24AM	Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why (Zacks)
Jan-09-24 08:44AM	DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING (PR Newswire)
Jan-08-24 06:30AM	Flagship Pioneering Debuts Enabling Technologies Initiative (PR Newswire)
06:30AM	Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine (PR Newswire)
Jan-05-24 09:00AM	Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies (GlobeNewswire)
Jan-03-24 04:05PM	Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +11.90%
Dec-19-23 09:01AM	EVP Christian Hordo Sells 75,000 Shares of Sana Biotechnology Inc (SANA) (GuruFocus.com) +13.60%
Dec-11-23 09:00AM	Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-01-23 04:05PM	Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System (GlobeNewswire)
Nov-27-23 07:01PM	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders (PR Newswire)
Nov-21-23 09:00AM	Sana Biotechnology to Present at November and December 2023 Investor Conferences (GlobeNewswire) -6.74%
06:00AM	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics (PR Newswire)
Nov-17-23 09:00AM	Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes (GlobeNewswire) +7.14%
Nov-09-23 04:05PM	Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis (GlobeNewswire)
Nov-08-23 04:05PM	Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire) -13.92%
Nov-02-23 09:05AM	Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-01-23 10:30AM	Flagship Pioneering Launches Pioneering Intelligence (PR Newswire)
Oct-19-23 10:30AM	Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines (PR Newswire)
Oct-10-23 04:15PM	Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M (GlobeNewswire) -8.95%
Oct-02-23 07:00AM	Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics (PR Newswire) -7.49%
Sep-27-23 08:31AM	Flagship Pioneering Named to Fortune's 2023 'Change the World' List (PR Newswire) +5.31%
Sep-11-23 06:30AM	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer (PR Newswire)
Aug-30-23 04:05PM	Sana Biotechnology to Present at September 2023 Investor Conferences (GlobeNewswire)
Aug-29-23 09:00AM	Invaio achieves first registration for citrus greening solution featuring Trecise technology (PR Newswire)
Aug-03-23 05:03PM	Sana: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Jun-16-23 09:00AM	Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting (GlobeNewswire)
May-31-23 04:05PM	Sana Biotechnology to Present at June 2023 Investor Conferences (GlobeNewswire)
May-22-23 07:33AM	Weekly biotech pulse: Sana, aTyr, Theseus to release fresh data (Investing.com) +5.76%
May-16-23 06:00AM	Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry (PR Newswire)
May-08-23 04:35PM	Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional (GlobeNewswire) +10.29%
04:26PM	Sana: Q1 Earnings Snapshot (AP Finance)
04:05PM	Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
May-04-23 01:56PM	7 High-Potential Penny Stocks in the Biotech Sector (InvestorPlace)
May-03-23 04:05PM	Sana Biotechnology to Present at May 2023 Investor Conferences (GlobeNewswire) +8.91%
09:55AM	Wall Street Analysts Believe Sana (SANA) Could Rally 83.17%: Here's is How to Trade (Zacks)

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHRISTIAN HORDO & KATHARINE HO	Officer	Jan 16 '25	Proposed Sale	3.86	75,000	289,500		Jan 16 04:31 PM
FMR LLC	See Remark 1	Jan 08 '25	Sale	6.49	290,912	1,887,320	4,541,511	Jan 10 01:32 PM
Wyrick Susan D.	See Remarks	Jan 02 '25	Option Exercise	0.00	5,000	0	155,512	Jan 03 04:15 PM
CHRISTIAN HORDO & KATHARINE HO	Officer	Dec 16 '24	Proposed Sale	1.89	75,000	141,750		Dec 16 04:33 PM
Hardy Nathan	Former CFO	Nov 26 '24	Proposed Sale	2.50	91,607	229,018		Nov 26 06:20 PM
NATHAN HARDY	Former CFO	Nov 25 '24	Proposed Sale	2.50	25,933	64,960		Nov 25 05:40 PM
NATHAN HARDY	Officer	Oct 21 '24	Proposed Sale	3.95	45,796	180,807		Oct 21 05:19 PM
Mulligan Richard	Director	Sep 24 '24	Sale	4.08	150,000	612,570	2,848,121	Sep 26 04:07 PM
Mulligan Richard	Director	Sep 25 '24	Sale	3.89	150,000	583,170	2,698,121	Sep 26 04:07 PM
RICHARD MULLIGAN	Director	Sep 25 '24	Proposed Sale	4.09	150,000	613,500		Sep 25 04:20 PM
RICHARD MULLIGAN	Director	Sep 24 '24	Proposed Sale	4.09	150,000	613,500		Sep 24 04:28 PM
Yang Patrick Y	Director	Mar 08 '24	Sale	9.45	25,000	236,300	149,250	Mar 11 04:57 PM
NELSEN ROBERT	Director	Feb 08 '24	Buy	5.50	1,818,181	9,999,996	12,446,022	Feb 12 05:46 PM
CRANDELL KEITH	10% Owner	Feb 08 '24	Buy	5.50	1,818,181	9,999,996	12,446,022	Feb 12 05:43 PM
ARCH Venture Fund X, L.P.	10% Owner	Feb 08 '24	Buy	5.50	1,818,181	9,999,996	12,446,022	Feb 12 05:43 PM

Open in Screener

BEAM

Beam Therapeutics Inc

Jan 30 • 04:00PM ET

27.28

Dollar change +1.37
Percentage change 5.29	%

Healthcare • Biotechnology • USA • NASD

BEAM Beam Therapeutics Inc daily Stock Chart

Peers: CRSP NTLA EDIT ALNY SRPT SGMO BLUE CLLS VYGR ADVM

| Held by: ARKK VTI IWM VB ARKG XBI VXF VBK IWN IBB

Index	RUT	P/E	-	EPS (ttm)	-1.76	Insider Own	12.35%	Shs Outstand	82.56M	Perf Week	3.77%
Market Cap	2.26B	Forward P/E	-	EPS next Y	-4.77	Insider Trans	-1.59%	Shs Float	72.58M	Perf Month	2.59%
Income	-143.59M	PEG	-	EPS next Q	-1.23	Inst Own	86.74%	Short Float	14.86%	Perf Quarter	22.06%
Sales	349.64M	P/S	6.46	EPS this Y	-172.38%	Inst Trans	6.02%	Short Ratio	9.08	Perf Half Y	-13.67%
Book/sh	9.58	P/B	2.85	EPS next Y	-1.79%	ROA	-11.67%	Short Interest	10.79M	Perf Year	-3.57%
Cash/sh	11.18	P/C	2.44	EPS next 5Y	-	ROE	-18.29%	52W Range	20.84 - 49.50	Perf YTD	10.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.58%	ROI	-15.27%	52W High	-44.89%	Beta	1.91
Dividend TTM	-	Quick Ratio	5.69	Sales past 5Y	54121.88%	Gross Margin	93.75%	52W Low	30.90%	ATR (14)	1.71
Dividend Ex-Date	Feb 04, 2014	Current Ratio	5.69	EPS Y/Y TTM	58.80%	Oper. Margin	-52.25%	RSI (14)	57.11	Volatility	5.54% 6.54%
Employees	436	Debt/Eq	0.20	Sales Y/Y TTM	328.73%	Profit Margin	-41.07%	Recom	1.76	Target Price	47.79
Option/Short	Yes / Yes	LT Debt/Eq	0.19	EPS Q/Q	3.53%	Payout	-	Rel Volume	0.87	Prev Close	25.91
Sales Surprise	-1.70%	EPS Surprise	1.12%	Sales Q/Q	-17.01%	Earnings	Nov 05 BMO	Avg Volume	1.19M	Price	27.28
SMA20	7.37%	SMA50	3.76%	SMA200	8.49%	Trades		Volume	1,033,829	Change	5.29%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$27 → $39
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy	$80
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130
Oct-19-21	Initiated	SVB Leerink	Outperform	$117
Sep-24-21	Resumed	Stifel	Buy	$85 → $120
Sep-10-21	Initiated	BofA Securities	Buy	$150
May-11-21	Initiated	Redburn	Buy

Show Previous Ratings

Today 07:00AM	Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference (GlobeNewswire) +5.29%
Jan-28-25 09:55AM	Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet (Zacks)
Jan-23-25 07:00AM	Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily) -8.77%
10:29AM	Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now? (Zacks)
07:00AM	Loading…
07:00AM	Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts (GlobeNewswire)
Dec-30-24 03:27PM	Why Is Beam Therapeutics Inc. (BEAM) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-29-24 06:28AM	Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Dec-17-24 07:00AM	Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-24 12:01PM	Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers (Insider Monkey)
Dec-09-24 11:10AM	Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains (Benzinga)
07:15AM	ASH24: Darzalex in smoldering myeloma, Mercks ADC data and Novos sickle cell drug (BioPharma Dive)
Dec-08-24 01:45PM	Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-07-24 11:30AM	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-06-24 07:00AM	Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer (GlobeNewswire) +5.49%
11:30AM	Loading…
Dec-05-24 11:30AM	Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report? (Zacks)
Dec-04-24 07:00AM	Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader (GlobeNewswire)
Nov-12-24 04:01PM	Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference (GlobeNewswire) -7.94%
Nov-07-24 06:26AM	Beam Therapeutics upgraded to Outperform from Market Perform at Leerink (TipRanks)
Nov-06-24 02:12AM	Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... (GuruFocus.com) +11.24%
01:40AM	Q3 2024 Beam Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-05-24 03:37PM	Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial (Benzinga)
09:00AM	Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
07:40AM	Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs (GlobeNewswire)
04:18AM	Sickle cell patient dies in Beam study of base editing therapy (BioPharma Dive)
Oct-31-24 03:50AM	Beam Therapeutics (BEAM): Promising Gene Editing Stock with Base Editing Technology (Insider Monkey)
Oct-29-24 06:30AM	Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting (GlobeNewswire)
Oct-23-24 08:47AM	Beam Therapeutics (BEAM): A Small-Cap Leader in Precision Genetic Medicine (Insider Monkey)
Oct-17-24 03:05PM	State Street Corp's Strategic Acquisition in Beam Therapeutics Inc (GuruFocus.com) -8.77%
11:31AM	Loading…
Sep-05-24 11:31AM	Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report? (Zacks)
Aug-14-24 10:27AM	Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine with CRISPR Technology (Insider Monkey)
Aug-09-24 10:19AM	3 Gene Editing Stocks with Potential to Transform Medicine (InvestorPlace)
Aug-07-24 10:50AM	Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss (Zacks)
Aug-06-24 01:54PM	BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)
07:45AM	Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-26-24 07:43AM	Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock? (Zacks)
Jul-24-24 06:28PM	Beam Therapeutics Stock Earns RS Rating Jump To 85 (Investor's Business Daily) +7.92%
08:53AM	CRISPR Therapeutics Nears 52-Week Low. Time to Buy? (TipRanks)
08:23AM	Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40 (InvestorPlace)
Jul-22-24 04:45PM	3 Gene Editing Stocks Shaping the Future of Medicine (InvestorPlace) +12.09%
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jul-16-24 10:12AM	Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines (Zacks) +6.52%
Jul-15-24 06:30AM	Beam Therapeutics Announces Transition of Chief Financial Officer (GlobeNewswire)
Jul-11-24 12:56PM	Here's Why You Should Invest in Beam Therapeutics (BEAM) Now (Zacks) +8.01%
Jul-09-24 12:00PM	Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
07:00AM	The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 (InvestorPlace)
06:25AM	3 Stocks With the Potential to 10X Your Money (InvestorPlace)
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jul-03-24 09:12AM	3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030 (InvestorPlace)
Jun-27-24 10:02PM	You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever. (InvestorPlace)
10:26AM	Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study (Zacks)
Jun-26-24 06:30AM	Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Jun-14-24 03:00AM	Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease (GlobeNewswire)
Jun-06-24 11:31AM	Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report? (Zacks)
May-30-24 06:30AM	Beam Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 04:00PM	Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress (GlobeNewswire)
May-13-24 02:18PM	15 Best ARK Stocks To Buy Now (Insider Monkey) +12.98%
May-09-24 06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
May-08-24 10:52AM	Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss (Zacks)
06:30AM	Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference (GlobeNewswire)
May-07-24 09:02PM	Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview (GuruFocus.com)
01:54PM	BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:17AM	Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates (MT Newswires)
06:30AM	Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results (GlobeNewswire)
May-01-24 10:01AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Mar-28-24 11:30AM	Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? (Zacks)
Mar-26-24 06:30AM	Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Feb-28-24 06:30AM	Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences (GlobeNewswire)
Feb-27-24 04:01PM	Beam Rockets 26%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug (Investor's Business Daily) +25.89%
02:57PM	Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat (Investor's Business Daily)
12:33PM	Beam Shares Rise As Q4 Results Beat Street (RTT News)
07:11AM	Beam Therapeutics Inc (BEAM) Reports Strong Year-End Financials with Key Clinical Milestones on ... (GuruFocus.com)
06:30AM	Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones (GlobeNewswire)
Feb-20-24 10:00AM	Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline (Zacks)
Feb-16-24 02:46PM	Beam Therapeutics Stock Shows Healthy Relative Strength Improvement (Investor's Business Daily)
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-07-24 07:35AM	3 Biotech Stocks to Buy on the Dip: February 2024 (InvestorPlace)
Feb-05-24 06:30AM	Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 06:21PM	Why Beam Therapeutics Stock Zoomed 17% Higher Today (Motley Fool) +16.47% -8.66%
Jan-16-24 01:51PM	Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market (InvestorPlace)
09:00AM	3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street (Motley Fool)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace)
Jan-08-24 06:30AM	Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones (GlobeNewswire) +6.87%
05:52AM	4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 (Motley Fool)
Jan-02-24 06:30AM	Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-23 10:30AM	2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street (Motley Fool)
Dec-15-23 10:22AM	11 Most Promising Biotech Stocks to Buy According to Analysts (Insider Monkey)
Dec-14-23 06:30AM	Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors (GlobeNewswire) +5.34%
Dec-08-23 11:30AM	Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report? (Zacks) -8.17%
Nov-30-23 09:55AM	Wall Street Analysts Believe Beam Therapeutics Inc. (BEAM) Could Rally 81.29%: Here's is How to Trade (Zacks)
Nov-23-23 11:03AM	Beam Therapeutics Inc's Chief Legal Officer Christine Bellon Sells 10,000 Shares (GuruFocus.com)
09:42AM	14 Best Short-Term Stocks to Invest In (Insider Monkey)
Nov-20-23 05:43PM	The 3 Best Gene Editing Stocks on the Frontier of Medicine (InvestorPlace) +11.98% -9.14%
Nov-18-23 07:15AM	Is Beam Therapeutics Stock a Buy Now? (Motley Fool)
06:49AM	3 Monster Stocks in the Making (Motley Fool)
Nov-17-23 12:00PM	What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock (Zacks) +10.81%
Nov-14-23 05:50AM	Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks (Motley Fool) +11.90%
Nov-10-23 09:55AM	Does Beam Therapeutics Inc. (BEAM) Have the Potential to Rally 139.76% as Wall Street Analysts Expect? (Zacks)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JOHN M EVANS	Officer	Jan 30 '25	Proposed Sale	26.75	30,000	802,482		Jan 30 04:12 PM
Bellon Christine	Chief Legal Officer	Jan 02 '25	Sale	24.68	1,241	30,628	102,968	Jan 06 05:49 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Jan 02 '25	Sale	24.68	1,117	27,568	43,814	Jan 06 05:48 PM
BETHANY J. CAVANAGH	Officer	Dec 31 '24	Proposed Sale	25.27	9,500	240,065		Dec 30 07:29 PM
CHRISTINE BELLON	Officer	Dec 31 '24	Proposed Sale	25.27	4,167	105,300		Dec 30 07:26 PM
Ciaramella Giuseppe	President	Dec 17 '24	Option Exercise	0.67	53,500	35,845	162,650	Dec 19 04:10 PM
Ciaramella Giuseppe	President	Nov 06 '24	Sale	26.36	51,110	1,347,050	109,150	Nov 08 04:10 PM
Ciaramella Giuseppe	President	Oct 14 '24	Option Exercise	2.00	41,754	83,594	211,370	Oct 16 04:44 PM
Ciaramella Giuseppe	President	Oct 14 '24	Sale	26.27	51,110	1,342,752	160,260	Oct 16 04:44 PM
Giuseppe Ciaramella	Officer	Oct 14 '24	Proposed Sale	24.65	102,220	2,519,723		Oct 15 11:37 AM
Burrell Terry-Ann	Officer	Oct 07 '24	Proposed Sale	23.00	185,565	4,267,995		Oct 07 05:00 PM
Bellon Christine	Chief Legal Officer	Oct 01 '24	Sale	23.48	385	9,040	104,209	Oct 02 05:52 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Oct 01 '24	Sale	23.48	289	6,785	44,931	Oct 02 05:51 PM
Evans John M.	CEO	Sep 30 '24	Sale	24.60	60,000	1,476,024	938,659	Oct 02 05:49 PM
JOHN M EVANS	Officer	Sep 30 '24	Proposed Sale	24.60	60,000	1,476,024		Sep 30 04:51 PM
Simon Amy	Chief Medical Officer	Jul 02 '24	Sale	22.95	748	17,167	68,805	Jul 03 04:05 PM
Simon Amy	Chief Medical Officer	Jul 01 '24	Sale	23.76	502	11,928	69,553	Jul 03 04:05 PM
Evans John M.	CEO	Jun 27 '24	Sale	24.50	60,000	1,470,156	998,343	Jun 28 04:15 PM
Simon Amy	Chief Medical Officer	Apr 02 '24	Sale	30.54	16,530	504,851	70,060	Apr 03 07:43 PM
Simon Amy	Chief Medical Officer	Apr 01 '24	Sale	32.13	7,157	229,954	86,590	Apr 03 07:43 PM
Bellon Christine	Chief Legal Officer	Apr 01 '24	Sale	32.12	3,401	109,240	104,594	Apr 03 07:40 PM
Burrell Terry-Ann	Chief Financial Officer	Apr 01 '24	Sale	32.12	5,446	174,926	70,137	Apr 03 07:39 PM
Evans John M.	CEO	Apr 01 '24	Sale	32.13	18,102	581,617	1,058,343	Apr 03 07:36 PM
Ciaramella Giuseppe	President	Apr 01 '24	Sale	32.12	4,534	145,632	169,616	Apr 03 07:33 PM
Evans John M.	CEO	Mar 28 '24	Sale	33.86	60,000	2,031,402	998,262	Apr 01 04:10 PM
FMR LLC	See Remark 1	Feb 14 '24	Sale	30.55	900,000	27,496,912	1,235,511	Feb 15 02:34 PM
FMR LLC	See Remark 1	Feb 13 '24	Sale	30.76	1,565	48,139	2,771,913	Feb 15 02:34 PM
Evans John M.	CEO	Jan 31 '24	Sale	25.33	60,000	1,519,800	1,058,262	Feb 02 04:05 PM

SANA

Sana Biotechnology Inc

BEAM

Beam Therapeutics Inc

Upgrade your FINVIZ experience